2021 EUnetHTA Forum Welcome Guide

The 2021 EUnetHTA Forum Welcome Guide is now available. The guide forms a comprehensive overview of EUnetHTA activities as we near completion of Joint Action 3, and is recommended reading prior to the Forum on 15 April. Follow the link, or check the ‘Get Involved’ dropdown menu on our homepage and then to ‘Events’, you’ll […]

2021 EUnetHTA Forum – Agenda

The 2021 EUnetHTA Forum takes place online on 15th April. In advance of this, please follow the link to access the agenda for the day’s events and speakers. 2021 EUnetHTA Forum Agenda Also, if you were unable to register and still wish to do so, please contact us directly at eunethta@zinl.nl See you there! EUnetHTA […]

Patient group input requested for new Rapid Reviews on medicinal products for COVID-19.

EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We believe patient groups can help us understand patients’ unique perspectives by collecting and presenting patients’ […]

EUnetHTA Magazine – Winter 2021 – now available

We are please to finally publish another issue of the EUnetHTA Magazine, a collection of articles submitted by members and stakeholders that deal with HTA in Europe, EUnetHTA tasks and output, and, of course, COVID-19 and the network’s reprioritization this year towards it. We normally try to publish quarterly. However, 2020 has proven to be […]

EUnetHTA – Open Letter of Comment

This is an open letter, written by the Chair of the EUnetHTA Executive Board, Niklas Hedberg. It expresses commentary on the role of EUnetHTA within European HTA, and that of scientific journals. Please access the letter here: EUnetHTA – Open Letter of Comment For any questions regarding this, please contact the EUnetHTA Secretariat team at eunethta@zinl.nl

Minutes of EMA/EUnetHTA virtual meeting

We are pleased to publish the minutes of the 13 July 2020 meeting held between the European Medicines Agency (EMA) and EUnetHTA. The meeting covered updates on EMA/EUnetHTA collaboration, JA3 final phase priorities, and 201-2021 Work Plan review, in addition to COVID-19 publication focus and other topics. Please access at this link: EMA-EUnetHTA July 2020 […]

EMA-EUnetHTA Bilateral Meeting July 2020 – minutes now available

We are pleased to publish the minutes of the 13 July 2020 meeting held between the European Medicines Agency (EMA) and EUnetHTA. The meeting covered updates on EMA/EUnetHTA collaboration, JA3 final phase priorities, and 201-2021 Work Plan review, in addition to COVID-19 publication focus and other topics. Please access at this link: EMA-EUnetHTA July 2020 […]

RCROT02 – Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19 – report now available

EUnetHTA is pleased to announce that the “Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19” is now available. This is the second rapid review assessing health technologies for SARS-CoV-2. The objective of this assessment was to identify, assess and summarise evidence on […]

OTCA28 – ‘Lung cancer screening in risk groups’ – final assessment now available

We are pleased to announce that the collaborative assessment, OTCA28 – ‘Lung cancer screening in risk groups’ – is now available. The aim of this EUnetHTA Assessment is to provide a reliable synthesis and analysis of the available evidence on lung cancer screening in risk groups (persons with history of smoking or current smokers, persons […]

PTJA10 – Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older – Final assessment now available

This is the pharmaceutical Joint Assessment PTJA10 – Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older. In October, 2020, the European Commission granted conditional marketing authorisation for Adakveo® (crizanlizumab) for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older. Publication of […]